好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Myasthenia Gravis Mimicking Stroke - Implications of Cognitive Errors and Clinical Factors
Neuromuscular and Clinical Neurophysiology (EMG)
P5 - Poster Session 5 (5:30 PM-6:30 PM)
12-032

To identify the clinical factors and cognitive errors that lead to the misdiagnosis of myasthenia gravis (MG) as stroke.

MG is an immune-mediated disorder characterized by fluctuating fatigue of skeletal muscles, often involving extrinsic ocular, bulbar muscles and at times presenting with hemibody/focal weakness thus mimicking a stroke. 

MG patients (2013-2017) with at least 1 year follow up were analyzed. Demographic and clinical characteristics were collected. The type of cognitive error, clinical factors contributing to the misdiagnosis as stroke were recorded. Diagnostic errors were categorized according to Patient Safety Network’s categories of cognitive bias. Statistical analysis was done using Fischer’s Exact test.

21 patients -13 women, 19 Caucasians (90.5%), mean age of 66.7+/-4.07 were included. 10 were MGFA class 3a, 7 were MGFA class 2b, 3 were MGFA3b. 18 patients were acetylcholine receptor antibody positive, 1 was MuSK positive. Slurred speech (8 patients, 38.1%) was the most common symptom that resulted in misdiagnosis, followed by hemibody weakness (7 patients, 33.3%), and dysphagia (3, 14.3%). Smoking (12, 57.1%) and hypertension (11, 52.4%) were common risk factors for stroke. Small vessel disease was suspected as the most common etiology (15, 71.4%).  10 patients received thrombolytic therapy and 16 patients were on antiplatelets. 4 patients who presented with recurrent symptoms were placed on anticoagulants. 18 patients presented with their symptoms acutely to the emergency department and 3 of them presented to the clinic. Availability bias due to lower threshold to diagnose stroke was the most common cognitive error (9 patients, p<0.05) followed by anchoring bias (7 patients, due to hemibody weakness) and premature closure (appropriate imaging was not ordered, 3 patients, p<0.05).

Acute presentation of bulbar symptoms and focal weakness to the emergency department results in misdiagnosis of MG as stroke. 

Authors/Disclosures
Natalie Kukulka, MD
PRESENTER
Dr. Kukulka has nothing to disclose.
No disclosure on file
Anudeep Yelam, MD Dr. yelam has nothing to disclose.
Elanagan Nagarajan, MD Dr. Nagarajan has nothing to disclose.
Raghav Govindarajan, MD, FAAN (HSHS St. Elizabeth Medical Group) Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MT pharma. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Catalyst. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche . Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amicus. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Govindarajan has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for MT pharma . Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Catalyst. Dr. Govindarajan has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Argenx. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biohaven. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Takeda. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Abbvie. The institution of Dr. Govindarajan has received research support from Band of Hope . The institution of Dr. Govindarajan has received research support from Alexion. Dr. Govindarajan has received publishing royalties from a publication relating to health care.